Tranilast directly targets NLRP3 to treat inflammasome‐driven diseases

Tranilast directly targets NLRP3 to treat inflammasome‐driven diseases

Abstract The dysregulation of NLRP3 inflammasome can cause uncontrolled inflammation and drive the development of a wide variety of human diseases, but the medications targeting NLRP3 inflammasome are not available in clinic. Here, we show that tranilast (TR), an old anti‐allergic clinical drug, is...

Full description

Bibliographic Details
Main Authors: Yi Huang, Hua Jiang, Yun Chen, Xiaqiong Wang, Yanqing Yang, Jinhui Tao, Xianming Deng, Gaolin Liang, Huafeng Zhang, Wei Jiang, Rongbin Zhou
Format: Article
Language:English
Published: Wiley 2018-04-01
Series:EMBO Molecular Medicine
Subjects:
directly bind
inflammasome‐driven diseases
inhibitor
NLRP3
tranilast
Online Access:https://doi.org/10.15252/emmm.201708689

Internet

https://doi.org/10.15252/emmm.201708689

Similar Items